Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like AAM Calls for Time Estimates, Clarifications in Supply Chain Waiver Guidance July 10, 2018 Pfizer Drops Half of Enrollment in Lyme Disease Trial Due to Sites’ GCP Infractions February 16, 2023 AstraZeneca Reaches $775 Million Settlement Resolving Ultomiris Patent Dispute March 17, 2022
Pfizer Drops Half of Enrollment in Lyme Disease Trial Due to Sites’ GCP Infractions February 16, 2023